Paasch C, De Santo G, Gamal-Eldin H N, Hünerbein M
University Hospital Brandenburg an der Havel, Brandenburg Medical University, Clinic for General and Visceral Surgery, Hochstraße 29, 14770, Brandenburg an der Havel, Germany.
Department of General Surgery, Oberhavel Kliniken Gransee, Meseberger Weg 12-13, 16775, Gransee, Brandenburg, Germany.
Ann Med Surg (Lond). 2021 Sep 15;70:102824. doi: 10.1016/j.amsu.2021.102824. eCollection 2021 Oct.
The prognosis of abdominal cancer with peritoneal carcinomatosis (PC) is poor. In literature, some authors described a repeated Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with recurrent PC as feasible for overall survival improvement. Hence, we implemented this approach at our hospital and analyzed our cases.
A unicentric retrospective observational study took place at the Helios hospital Berlin-Buch in 2020. The data of individuals who received a HIPEC in the time of 2007-2019 were extracted. The data were entered in the HIPEC database of the German Society of General and Visceral Surgery (StuDoQ|HIPEC, German society for general and visceral surgery). The primary objective was the overall survival after first HIPEC procedure.
A total of 292 data files from were extracted and 14 patients were identified as eligible for further analysis (7× colorectal, 3x gastric, 1× appendix cancer, 1× cancer of unknown primary, 1× Mesothelioma, 1× Pseudomyxoma peritonei). The mean age was 57 (8) years. The BMI was on average 23.5 (3.5) kg/m. A total of 8 individuals were female and 6 male (6xASA-Score I, 8xASA-Score II). The initial Peritoneal Cancer Index (PCI) was on average 11.5 (9.1). The average overall survival after 1. HIPEC for colonic cancer was 74 months (n = 3; 43, 70 and 90 month), for gastric cancer 29 months (n = 2; 19 and 39 month) and for mesothelioma 44 months (n = 1).
Based on our findings Repeated Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy may improve overall survival of selected patients suffering from peritoneal carcinomatosis.
伴有腹膜癌转移（PC）的腹部癌症预后较差。在文献中，一些作者描述了对复发性PC患者进行重复减瘤手术（CRS）联合热灌注腹腔内化疗（HIPEC）对提高总生存率是可行的。因此，我们在我院实施了这种方法并分析了我们的病例。
2020年在柏林-布赫的赫利俄斯医院进行了一项单中心回顾性观察研究。提取了2007年至2019年期间接受HIPEC治疗的患者的数据。这些数据被录入德国普通和内脏外科学会的HIPEC数据库（StuDoQ|HIPEC，德国普通和内脏外科学会）。主要目标是首次HIPEC手术后的总生存率。
共提取了292个数据文件，14例患者被确定符合进一步分析的条件（7例结直肠癌、3例胃癌、1例阑尾癌、1例原发灶不明癌、1例间皮瘤、1例腹膜假黏液瘤）。平均年龄为57（8）岁。BMI平均为23.5（3.5）kg/m²。共有8名女性和6名男性（6例ASA评分I级、8例ASA评分II级）。初始腹膜癌指数（PCI）平均为11.5（9.1）。结肠癌患者首次HIPEC后的平均总生存期为74个月（n = 3；43、70和90个月），胃癌患者为29个月（n = 2；19和39个月），间皮瘤患者为44个月（n = 1）。
基于我们的研究结果，重复减瘤手术联合热灌注腹腔内化疗可能会提高部分腹膜癌转移患者的总生存率。
